Dr Paolo A. Ascierto, director of the Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy at the National Tumor Institute Fondazione G. Pascale in Naples, Italy presented the updated 7-year results of the phase III CheckMate 238 trial with adjuvant nivolumab versus ipilimumab in resected stage III/IV melanoma.
With the educational support of:
 |
 |
 |
 |